Program
risovalisib
Also written as “CYH33” and “CYH33 for tablet”.
Its studies are mostly in Ovarian Neoplasms · Vascular Malformations, led by Haihe Biopharma.
Furthest: phase 2, since Aug 30, 20214 company-led studies, 2 open or runningNext primary completion: Dec 31, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haihe Biopharma | 42 open or running | phase 2since Aug 30, 2021 | May 22, 2018 | Dec 31, 2029phase 2 · NCT06975618 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 22, 2018First study: phase 1 study in Advanced Solid TumorsFirst studyNCT03544905 · 206 enrolled · China
- Aug 25, 2020Phase 1 study in Ovarian NeoplasmsNCT04586335 · 24 enrolled · United States, Australia, China
- Aug 30, 2021Phase 2 study in Ovarian NeoplasmsNCT05043922 · 93 enrolled · China, Japan
- Apr 28, 2025Phase 2 study in PIK3CA-Related Overgrowth Spectrum (PROS)NCT06975618 · 141 planned · China, Japan
Ahead
- Dec 31, 2029Primary completion: phase 2 study in PIK3CA-Related Overgrowth Spectrum (PROS)NCT06975618
TargetBeta
PIK3CA →read by rule
“An orally bioavailable selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), ”NCIt, by rule
Other programs on PIK3CA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Alpelisibrule | Novartis | phase 4 | 37 |
| inavolisibrule | Hoffmann-La Roche | phase 3 | 20 |
| tersolisib | Eli Lilly | phase 3 | 10 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K-alpha Inhibitor JS105rule | risen-suzhou-pharma-tech-co-ltd | phase 3 | 1 |
| serabelisibrule | Takeda | phase 2 | 11 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
| zovegalisibrule | relay-therapeutics-inc | phase 2 | 2 |
| Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rule | pikavation-therapeutics-inc | phase 2 | 1 |
| Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636rule | ensem-therapeutics | phase 2 | 1 |
| RAS/PI3K-alpha Inhibitor VVD-159642rule | Bayer | phase 1 | 1 |
| PI3Ka H1047R Mutant Selective Inhibitor CGT6297rule | cogent-biosciences-inc | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06975618PIK3CA-Related Overgrowth Spectrum (PROS) · China, Japan | 2 | Recruiting | Dec 31, 2029 | 141 |
| NCT05043922Ovarian Neoplasms · China, Japan | 2 | Active, not recruiting | Jul 31, 2024 | 93 |
| NCT04586335Ovarian Neoplasms · United States, Australia, China | 1 | Terminated | Feb 15, 2023 | 24 |
| NCT03544905Advanced Solid Tumors · China | 1 | Completed | Dec 4, 2024 | 206 |
How it is read
Names in the registry
- “CYH33”, 3 entries
- “CYH33 for tablet”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 2 studies
- Vascular Malformations, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.